Sigyn Therapeutics Free Cash Flow (FCF) History (SIGY)

Sigyn Therapeutics reported −$1.8M in free cash flow for fiscal 2022, a decrease of $27,656 from the previous fiscal year.

View full Sigyn Therapeutics company overview

Sigyn Therapeutics free cash flow by year

Sigyn Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20222022-12-31−$1.8M−$27,656——
20212021-12-31−$1.8M———
20182018-12-31−$289,062$111,881—−1019.69%
20172017-12-31−$400,943——−1043.20%
20152015-12-31−$86,271−$38,366—−295.38%
20142014-12-31−$47,905——−111.01%

Sigyn Therapeutics free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$400,943 to −$1.8M, a net decrease of $1.4M. Sigyn Therapeutics's latest reported quarter, Q3 2022, generated −$524,168 in free cash flow, an increase of $32,853 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Sigyn Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about SIGY yet. Start the conversation.

Write the first post